SHTPY (Schott Pharma AG KGaA) Beginning Cash Position: $28 Mil (As of Mar. 2026)


SHTPY Schott Pharma AG & CO KGaA SHTPY
64 GF Score
Price $4.37
GF Value $7.02
! 2 Warning Signs
View Full Analysis

What is Schott Pharma AG KGaA Beginning Cash Position?

Schott Pharma AG KGaA SHTPY -42.88% 64 Beginning Cash Position is $28 Mil as of Mar. 2026. GuruFocus rates SHTPY with a GF Score™ of 64/100 and a GF Value™ of $7.02. The stock has 2 warning signs investors should review.

Schott Pharma AG KGaA's Beginning Cash Position for the quarter that ended in Mar. 2026 was $28 Mil.

Schott Pharma AG KGaA's quarterly Beginning Cash Position declined from Sep. 2025 ($33 Mil) to Dec. 2025 ($26 Mil) but then increased from Dec. 2025 ($26 Mil) to Mar. 2026 ($28 Mil).

Schott Pharma AG KGaA's annual Beginning Cash Position declined from Sep. 2023 ($31 Mil) to Sep. 2024 ($27 Mil) but then increased from Sep. 2024 ($27 Mil) to Sep. 2025 ($27 Mil).

Schott Pharma AG KGaA Beginning Cash Position Related Terms

Schott Pharma AG KGaA Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Schott Pharma AG KGaA's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Schott Pharma AG KGaA Beginning Cash Position Chart

Schott Pharma AG KGaA Annual Data
Trend Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Beginning Cash Position
Get a 7-Day Free Trial 21.89 27.58 30.73 27.03 27.21

Schott Pharma AG KGaA Quarterly Data
Sep20 Sep21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.14 30.09 33.20 26.31 28.43
SHTPY
64GF Score
Schott Pharma AG & CO KGaA SHTPY
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Schott Pharma AG KGaA Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $28 Mil mean?
Schott Pharma AG KGaA (SHTPY) has a Beginning Cash Position of $28 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Schott Pharma AG KGaA and its competitors.
Is Schott Pharma AG KGaA's Beginning Cash Position too high?
Schott Pharma AG KGaA's current Beginning Cash Position is $28 Mil. Overall, Schott Pharma AG KGaA has a GF Score™ of 64/100, reflecting its overall financial health beyond just this single metric.
How does Schott Pharma AG KGaA's Beginning Cash Position compare to ISRG and BDX?
Schott Pharma AG KGaA's Beginning Cash Position of $28 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Medical Devices & Instruments company?
A good Beginning Cash Position depends on the Medical Devices & Instruments industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Schott Pharma AG KGaA and its competitors. Schott Pharma AG KGaA's current Beginning Cash Position is $28 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Schott Pharma AG KGaA stock overvalued right now?
Schott Pharma AG KGaA (SHTPY) has a current Beginning Cash Position of $28 Mil. The stock's GF Value™ is $7.02, compared to a current price of $4.37 — trading 37.7% below its estimated fair value. The current Beginning Cash Position is $28 Mil. Schott Pharma AG KGaA's overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Schott Pharma AG KGaA (SHTPY), the current Beginning Cash Position is $28 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Schott Pharma AG KGaA (SHTPY) Overvalued in 2026?

Based on GuruFocus' analysis, Schott Pharma AG KGaA stock appears to be undervalued. The current stock price of $4.37 is trading 37.7% below its estimated GF Value™ of $7.02.

Key valuation signals for SHTPY:

  • Beginning Cash Position: $28 Mil
  • GF Value™: $7.02 vs. price of $4.37 (37.7% below fair value)
  • GF Score™: 64/100 with 2 warning signs

No single metric tells the full story. See the SHTPY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Schott Pharma AG KGaA Business Description

Address Hattenbergstrasse 10, Mainz, RP, DEU, 55122
Schott Pharma AG & CO KGaA is an international provider of drug containment solutions and delivery systems for injectable drugs for pharma, biotech and life-sciences. Its business operates in two segments: Drug Containment Solutions (DCS) and Drug Delivery Systems (DDS). The majority of revenue is being generated from the DCS segment, which includes products like vials, cartridges, and ampoules, and provides customers with sterile and non-sterile options in standard and high-end formats for drug storage. Geographically, the company generates revenue from Europe, the Middle East, Africa (EMEA), Asia and the South Pacific, North America, and South America.
64GF Score

Get the complete analysis for SHTPY

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.37
Price
$7.02
GF Value